

Inhaled Nitric Oxide Market 2022 | North America region would exhibit the highest CAGR of 8.3% by 2027

Inhaled Nitric Oxide Market Expected to Reach \$634.4 Million by 2027

PORTLAND, OREGON, UNITED STATE, August 4, 2022 /EINPresswire.com/ -- According to a new report published by Allied Market Research, titled, "[Inhaled Nitric Oxide Market](#) by Application : Opportunity Analysis and Industry Forecast, 2020-2027," the global inhaled nitric oxide market size was valued at \$634.4 million in 2019, and is projected to reach \$1,180.98 million by 2027, growing at a CAGR of 8.1% from 2020 to 2027.



Global Inhaled Nitric Oxide Market
OPPORTUNITIES AND FORECAST, 2020-2027

Global Inhaled Nitric Oxide Market size is expected to reach **\$1180.98 Million** by 2027.

Growing at a **CAGR of 8.1%** (2020-2027)

Inhaled Nitric Oxide Market

Do Enquiry for Sample Report @ <https://www.alliedmarketresearch.com/request-sample/3020>

□□□ □□ □□ □□% □□□□□□□□, □□□□ □□□ □□□□ □□ □□□□□□ □□□□.

Inhaled nitric oxide (iNO) is a pulmonary vasodilator that plays a major role in regulating vascular muscle tone. It has emerged as a treatment for hypoxemic respiratory failure in newly born infants that is associated with persistent high pulmonary vascular pressure and resultant right-to-left shunting of blood (persistent pulmonary hypertension of the newborn. For instance- each year around 2% of all live births and >33% of neonatal mortality occurs due to neonatal hypoxic respiratory failure (HRF). On the other hand, 0.4-6.8/1000 live birth-years suffer from persistent pulmonary hypertension of the newborn (PPHN) and the mortality rate remains approximately 10% in those with moderate to severe forms of the condition. Neonatal hypoxic respiratory failure is caused by persistent pulmonary hypertension of the newborn and other diseases such as meconium aspiration syndrome, sepsis, birth asphyxia, and respiratory distress syndrome that contribute to pulmonary arterial hypertension. Inhaled nitric oxide (iNO) was first used in neonatal practice in 1992. It was approved by the U.S. Food and Drug Administration (US FDA) for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in 1999.

By region, the inhaled nitric oxide market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, and rest of Europe), Asia-Pacific (Japan, Australia, and rest of World)

COVID-19 pandemic, Inhaled nitric oxide has antiviral properties and improved oxygenation. Therefore, nitric oxide is now being tested as an experimental treatment for COVID-19. It is also helpful in protecting healthcare workers on the front line of the pandemic from getting sick. Further, iNO is used for the treatment of pulmonary hypertension, ARDS, and other respiratory diseases, whereas several undergoing randomized clinical trials are being conducted to investigate the role of inhaled nitric oxide in COVID-19. Moreover, key players such as Mallinckrodt have also initiated a retrospective study for the use of iNO in COVID-19 patients. Moreover, multiple ongoing clinical trials are conducted for iNO as a treatment for COVID-19 and it is being used with promising results in the patient population.

In March, the US FDA gave a handful of pharmaceutical company's emergency clearance to allow the use of their nitric oxide devices to treat these patients, including Bellerophon Therapeutics and Vero Biotech. In addition, inhaled gas can have therapeutic benefits in COVID-19 patients by preventing further damage to the vessels inside the lungs.

Key Findings Of The Study

By application, the neonatal respiratory treatment accounted for nearly 85.36% share of the inhaled nitric oxide market in 2019.

The chronic obstructive pulmonary disease is anticipated to grow with the CAGR 7.2 % throughout the forecast period.

North America accounted for 85.43% share of the market in 2019.

Asia-Pacific is anticipated to grow at a CAGR of 6% rate during the analysis period.

However, Asia-Pacific is expected to be growing region shortly on account of the number of highest live birth per 1000 people and the rise in prevalence of respiratory distress syndrome, neonatal jaundice, and hypoxic respiratory failure associated with persistent pulmonary hypertension of the newborn (PPHN). Furthermore, competitive market is formed due to the emergence of local providers of nitric oxide therapy systems contributes toward the Asia-Pacific inhaled nitric oxide market growth.

Key Market Segments

By Application

Neonatal Respiratory Treatment

Chronic Obstructive Pulmonary Disease (COPD)

Acute Respiratory Distress Syndrome (ARDS)

Others

Key Market Players

AIR LIQUIDE S.A.
BELLEROPHON THERAPEUTICS, INC.
BOC HEALTHCARE
BEYOND AIR, INC.
HALMA PLC
LINDE PLC (PRAXAIR, INC.)
MALLINCKRODT PLC
NOVOTERIS, LLC
VERO BIOTECH LLC
NU-MED PLUS

Get Customized Report @ <https://www.alliedmarketresearch.com/request-for-customization/3020>

North America Inhaled Nitric Oxide Market
Japan Inhaled Nitric Oxide Market
South Korea Inhaled Nitric Oxide Market
Singapore Inhaled Nitric Oxide Market
Australia Inhaled Nitric Oxide Market
Europe Inhaled Nitric Oxide Market
China Inhaled Nitric Oxide Market
Indonesia Inhaled Nitric Oxide Market
Taiwan Inhaled Nitric Oxide Market

□□□□□ □□□□□□□□ □□□□□□□□:

[Safety Needles Market](#)

[Digital Wound Measurement Devices Market](#)

About Us

Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.

David Correa
Allied Analytics LLP
800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/584391483>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.